The rising cancer incidence rate in China poses a substantial public health concern,
although there have been remarkable improvements in the country's cancer mortality and …

Gastric cancer is a leading contributor to cancer incidence and mortality globally. Recently,
artificial intelligence approaches, particularly machine learning and deep learning, are …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

Background Conventional immunohistochemistry technologies were limited by the inability
to simultaneously detect multiple markers and the lack of identifying spatial relationships …

Neutrophils, the most abundant and efficient defenders against pathogens, exert opposing
functions across cancer types. However, given their short half-life, it remains challenging to …

The sole use of single modality data often fails to capture the complex heterogeneity among
patients, including the variability in resistance to anti-HER2 therapy and outcomes of …

Background The widespread use of Immune checkpoint-inhibitors (ICI) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …

Background The investigational use of zolbetuximab (IMAB362), a groundbreaking
monoclonal antibody medication targeting claudin 18.2 (CLDN18. 2), for treatment of …

Tissue imaging has become much more colourful in the past decade. Advances in both
experimental and analytical methods now make it possible to image protein markers in …

Gastric cancer presents substantial management challenges, and the advent of
immunotherapy has ignited renewed hope among patients. Nevertheless, a significant …